Hamps Bio IPO Allotment Status: Key Details and Updates

Hamps Bio Limited, a pharmaceutical marketing and distribution company, recently concluded its Initial Public Offering (IPO), attracting significant investor interest. With its shares set to be listed soon, investors are keen to check their allotment status and understand the next steps. This article provides all the essential details about the Hamps Bio IPO allotment, listing, and performance expectations.

Hamps Bio IPO Overview

1. IPO Details

IPO Period: December 13 to December 17, 2024.
Issue Size: ₹24.96 crore.
Price Band: ₹51 per equity share.
Listing Platform: BSE SME.
Listing Date: Scheduled for December 20, 2024.

How to Check Hamps Bio IPO Allotment Status

1. Through the Registrar’s Website (Bigshare Services)

Hamps Bio’s IPO allotment process is managed by Bigshare Services. Follow these steps:

Visit the Bigshare Services IPO Allotment Page.
Select "Hamps Bio Limited IPO" from the dropdown menu.
Enter your PAN, application number, or DP Client ID.
Click "Search" to view your allotment status.

2. Through the BSE Website

Alternatively, investors can check the allotment status on the BSE website:

Visit the BSE IPO Allotment Page.
Select Equity and choose "Hamps Bio Limited" from the dropdown.
Enter your application number and PAN.
Click "Search" to check your status.

Post-Allotment Timeline

Credit of Shares: Allotted shares will be credited to investors' Demat accounts by December 19, 2024.
Refunds: Refunds for unsuccessful applications will also be processed by December 19, 2024.
Listing Date: Shares are set to debut on the BSE SME platform on December 20, 2024.

Grey Market Premium (GMP)

Current GMP

As of December 18, 2024, the Grey Market Premium (GMP) for Hamps Bio IPO is ₹55, suggesting a potential listing price of ₹106 against the issue price of ₹51. This indicates a potential 107.8% listing gain, reflecting strong demand in the unlisted market.

Note: GMP is speculative and may not guarantee actual listing performance.

Company Overview

Hamps Bio Limited focuses on marketing and distributing pharmaceutical products across India. The company’s strong industry presence and growing demand for healthcare solutions have fueled investor confidence.

Key Financial Metrics

Revenue Growth: Consistent growth with a solid order book in FY2024.
Profit Margins: Improved operational efficiencies have enhanced profitability.
Market Position: A trusted name in the pharmaceutical distribution sector.

Why Invest in Hamps Bio IPO?

Growth Potential: Increasing demand for pharmaceuticals positions Hamps Bio for long-term success.
Profitability: The company’s streamlined operations support steady financial growth.
Strong Grey Market Activity: The high GMP indicates positive investor sentiment.

FAQs About Hamps Bio IPO Allotment

1. When was the Hamps Bio IPO allotment finalized?

The IPO allotment was finalized on December 18, 2024.

2. How can I check my Hamps Bio IPO allotment status?

You can check your allotment status on the Bigshare Services or BSE websites using your PAN or application details.

3. When will the shares be listed?

The shares will be listed on the BSE SME platform on December 20, 2024.

4. What is the expected listing gain?

Based on the current Grey Market Premium (GMP) of ₹55, the stock could list at ₹106, offering a potential gain of 107.8%.

Conclusion

The Hamps Bio IPO has generated strong investor interest, reflected in its robust Grey Market Premium and positive market sentiment. With a strategic focus on pharmaceutical distribution and consistent financial performance, Hamps Bio holds potential for long-term growth. Investors are advised to stay informed about listing updates and market conditions to make informed decisions.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Please consult with a financial advisor for personalized investment guidance.

Next Ventive Hospitality IPO: Key Details and Insights for Investors

Hamps Bio IPO Allotment Status: Key Details and Updates